Michael Chi Sells 17,304 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Michael Chi sold 17,304 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $31.00, for a total value of $536,424.00. Following the completion of the transaction, the insider now directly owns 193,601 shares in the company, valued at approximately $6,001,631. This represents a 8.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Chi also recently made the following trade(s):

• On Friday, January 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.07, for a total value of $174,724.13.
• On Tuesday, December 24th, Michael Chi sold 17,303 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.97, for a total value of $483,964.91.
• On Thursday, December 19th, Michael Chi sold 7,500 shares of Hims & Hers Health stock. The shares were sold at an average price of $26.00, for a total value of $195,000.00.
• On Tuesday, December 10th, Michael Chi sold 7,259 shares of Hims & Hers Health stock. The shares were sold at an average price of $32.25, for a total value of $234,102.75.
• On Monday, December 2nd, Michael Chi sold 2,054 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.56, for a total value of $68,932.24.

Hims & Hers Health Price Performance

Shares of HIMS opened at $30.89 on Friday. Hims & Hers Health, Inc. has a one year low of $8.51 and a one year high of $35.02. The company has a 50-day simple moving average of $28.22 and a two-hundred day simple moving average of $22.18. The firm has a market capitalization of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the business posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% compared to the same quarter last year. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Wellington Management Group LLP increased its stake in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in shares of Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after purchasing an additional 328,142 shares in the last quarter. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health during the third quarter valued at approximately $5,531,000. Finally, Blueshift Asset Management LLC increased its stake in shares of Hims & Hers Health by 834.8% during the third quarter. Blueshift Asset Management LLC now owns 245,013 shares of the company’s stock valued at $4,513,000 after purchasing an additional 218,804 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HIMS shares. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Needham & Company LLC upped their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Finally, Piper Sandler upped their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.